Black Diamond Therapeutics, Inc. Altman Z-Score
BDTX|Modified Z-Score (book value) based on FY2020 data
Black Diamond Therapeutics, Inc.'s Altman Z-Score of 5.60 places the company in the "safe zone" used by the Altman model (above 2.9) for FY2020.
Based on SEC 10-K filings.
Key Data Points
- Piotroski F-Score: 2/9 criteria passed
- Altman Z-Score 5.60 (safe zone, above 2.9 threshold)
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
Safe Zone (> 2.9)
The score is above the 2.9 boundary used in the Altman model.
The Altman Z-Score uses 5 financial ratios. Learn more
Components: book value of equity, working capital, retained earnings, EBIT, and revenue-to-assets — all derived from SEC FY2020 10-K filings.
5-Factor Decomposition
Working Capital / Total Assets
- Ratio
- 0.926
- Weight
- 0.717
- Contribution
- 0.664
Retained Earnings / Total Assets
- Ratio
- -0.359
- Weight
- 0.847
- Contribution
- -0.304
EBIT / Total Assets
- Ratio
- -0.211
- Weight
- 3.107
- Contribution
- -0.656
Book Equity / Total Liabilities
- Ratio
- 14.045
- Weight
- 0.420
- Contribution
- 5.899
Revenue / Total Assets
- Ratio
- 0.000
- Weight
- 0.998
- Contribution
- 0.000
| Component | Ratio | Weight | Contribution |
|---|---|---|---|
| Working Capital / Total Assets | 0.926 | 0.717 | 0.664 |
| Retained Earnings / Total Assets | -0.359 | 0.847 | -0.304 |
| EBIT / Total Assets | -0.211 | 3.107 | -0.656 |
| Book Equity / Total Liabilities | 14.045 | 0.420 | 5.899 |
| Revenue / Total Assets | 0.000 | 0.998 | 0.000 |
| Total Z-Score | 5.60 | ||
As of FY2020 · SEC Form 10-K · Last checked Jun 21, 2026
Z-Score Zones
Safe Zone - score above the 2.9 boundary used in the Altman model.
Grey Zone - score between the 1.23 and 2.9 boundaries used in the Altman model.
Distress Zone - score below the 1.23 boundary used in the Altman model.